Ex-chemistry professor to run for Congress – Chemistry World (subscription)

Former chemistry professor Phil Janowicz is running for Congress for the first time in an attempt to unseat Republican Ed Royce, who has been a Californian representative for 25 years. Janowicz says he is running for Congress to oppose Trumps agenda, noting that his opponent has voted in lockstep with the president. The congressional election takes place in November 2018.

As a chemistry teacher here at California State Fullerton, I was constantly amazed by the grit and determination of my students, Janowicz said in a speech at the university on 25 April to announce his Democratic candidacy. When I learned how many of my students were struggling to meet basic food and housing needs, I decided that I had to do more than teach chemistry.

Janowicz tells Chemistry World that he was deeply affected by the plight of his students, even beyond the issue of crippling student loan debt. He recounts how many of those he taught were afraid for their parents to attend graduation due to concerns about deportation. The students, themselves US citizens, were fearful that their parents would be put at risk by attending because they lacked proper documentation.

After beginning his teaching at California State Fullerton in 2010, Janowicz left academia shortly after securing tenure to launch an education consultancy in January 2017.

In announcing his candidacy, Janowicz said he is running for Congress to resist the Trump agenda, and criticised his opponents record of voting with Trump 96% of the time. This was an apparent reference to a figure put forward by the polling data analysis website FiveThirtyEight to reflect how often Royce voted in line with the presidents positions.

Janowicz is concerned about the lack of scientists and individuals with science, technology, engineering and mathematics backgrounds in Congress. We need to tackle the problems of today with data we need to bring scientists back into public office, he says. Janowicz points to a proposal from the Trump administration to pull the earth science division out of Nasa, and warns that this will stymie the agencys ability to gather critical data from its satellites. If they cant collect the data, we cant even report on what is going on, he says.

Nevertheless, Janowicz acknowledges that going up against a Washington DC career politician will not be easy. He has raised about $30,000 (23,000) over the past few days, and the goal is at least $200,000 by late June when the filing period ends. Meanwhile, records indicate that Royces campaign has raised over $2.8 million.

See more here:
Ex-chemistry professor to run for Congress - Chemistry World (subscription)

Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? – Zacks.com

Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report first-quarter 2017 results later this month. The companys earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one. The company had an average negative surprise of 3.23% in the last four quarters.

Pumas shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 27.2% so far this year, while the industry recorded an increase of 5.5%.

In the last reported quarter, Puma posted a negative surprise of 0.99%. Lets see how things are shaping up for this announcement.

Factors at Play

Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib, its lead pipeline candidate.

The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer in patients who have previously been treated with Herceptin-based adjuvant therapy.

Moreover, several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.

In Apr 2017, Puma presented encouraging additional data from breast cancer studies at the San American Association for Cancer Research Annual (AACR) on neratinib. These include interim data from a phase II study in patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy; interim phase I/II data from the NSABP FB-10 trial of neratinib plus Kadcyla (T-DM1) in HER2-positive MBC; and phase II data from SUMMIT study in HER2-negative breast cancer patients with HER2 mutations.

Puma anticipates more data updates in the second quarter. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

Earnings Whispers

Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP:TheEarnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.08. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank:Puma Biotechs carries a Zacks Rank #4 (Sell). As it is that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Other Stocks That Warrant a Look

Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.

Conatus Pharmaceuticals Inc. (CNAT - Free Report) is scheduled to release results on May 4. The company has an Earnings ESP of +57.14% and a Zacks Rank #3. You can seethe complete list of todays Zacks #1 Rank stocks here.

ImmunoGen, Inc. (IMGN - Free Report) is scheduled to release results on May 5. The company has an Earnings ESP of +8.33% and a Zacks Rank #3.

FIBROGEN INC (FGEN - Free Report) is scheduled to release results on May 8. The company has an Earnings ESP of +23.81% and a Zacks Rank #3.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

See the original post:
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? - Zacks.com

iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. – The Cerbat Gem


BBNS
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc.
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research report report published on Wednesday, April 5th. They currently have $298.93 target ...
iShares NASDAQ Biotechnology Index (IBB) Stake Increased by ...Markets Daily
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc.Transcript Daily
iShares NASDAQ Biotechnology Index (IBB) Stock Rating Upgraded ...Sports Perspectives
BBNS -Chaffey Breeze -Petro Global News 24
all 16 news articles »

See original here:
iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. - The Cerbat Gem

Kenyan scientists push for female farmers’ access to biotechnology – Genetic Literacy Project

Dr. Felister Makini, Deputy Director General (crops) at the Kenya Agricultural & Livestock Research Organization (KALRO), noted that African women play a critical role in ensuring food security. She urged the government to make farming easier for them by providing modern tools such as biotechnology. As African women, we are the ones who suffer most whenever drought and food shortages strike, despite the availability of technological solutions to these problems, she said. We need to speak with one voice and advocate for a predictable policy environment. I have children and a family to protect. I cannot advocate for something that I know would affect them she added.

On her part, Prof. Caroline Thoruwa, Chairperson, African Women in Science and Engineering (AWSE), noted that for Africa to advance in agri-biotech, women must be involved. It is time to tell the public about the positive side of biotechnology. We need to raise up the status of women in biotechnology and also encourage women to network in order to achieve the noble goal of sharing their science, she said.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:AFRICAN WOMEN IN BIOSCIENCES CALL FOR SUPPORTIVE POLICIES ON BIOTECHNOLOGY

For more background on the Genetic Literacy Project, read GLP on Wikipedia

See the article here:
Kenyan scientists push for female farmers' access to biotechnology - Genetic Literacy Project

Rodman & Renshaw Reiterates Buy Rating for Cellect … – The Cerbat Gem


The Cerbat Gem
Rodman & Renshaw Reiterates Buy Rating for Cellect ...
The Cerbat Gem
Rodman & Renshaw reissued their buy rating on shares of Cellect Biotechnology Ltd. American Depositary Shares (NASDAQ:APOP) in a research report ...
Stocks Given Top Analysts Ratings: Cellect Biotechnology Ltd. (:APOP) FuelCell Energy, Inc. (NASDAQ:FCEL)Rives Journal
Cellect Gets Green Light From FDA For ApoGraft IND Submission in ...GlobeNewswire (press release)

all 3 news articles »

Read the rest here:
Rodman & Renshaw Reiterates Buy Rating for Cellect ... - The Cerbat Gem

Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology – Equity Research Is Published In The … – Exchange News Direct

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main raw material. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today).

Frost & Sullivan publishes equity research reports on technology, biomed and healthcare companies that are listed on the TASE, within the framework of the analysis program that the TASE has initiated. Key goals of the program are enhancing global awareness of these companies and enabling more informed investment decisions by investors interested in hot Israeli hi-tech and healthcare companies.

In the coming months, Frost & Sullivan will release 9 additional initiation coverage reports, covering the other companies that have joined the programme: 6 biomed companies Aposense, Brainsway, BiolineRX, Kitov Pharmaceuticals, D.N.A. Biomedical Solutions, and Redhill Biopharma; and 3 technology companies: Safe-T Group, Vonetize and Energix Renewable Energies.

For the purpose of equity research services, Frost & Sullivan, the leading global consulting, and market research firm, will leverage relevant analysts, experts and growth consultiants among a staff of 1,800, at ca. 50 branches across 6 continents, including in Israel. Frost & Sullivan will utilize the experience and know-how accumulated over the course of 55 years in medical technologies, life sciences, technology, energy, and other industrial fields, including the publication of tens of thousands of market and technology research reports, and economic analyses and valuations.

Starting September 2016 Edison Investment Research released analyses of 11 companies, and a significant increase in trading volume and in the exposure of the companies included in the project to both the local and foreign investing public is evident. It is noteworthy that in most of the reviewed dual listings, trading volume has increased significantly both in Israel and the United States.

See the original post here:
Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology - Equity Research Is Published In The ... - Exchange News Direct

Around the Pier: The Bioengineering Behind the Beauty – Scripps Oceanography News

Marine phytoplankton are famously photogenic.

Take, for instance, diatoms. They are among the most common type of phytoplankton and are especially breathtaking: their cell walls are made of silica, a glass-like compound, and take a variety of forms including discs, tubes, and star-like structures.

Scientists have long sought to understand the factors that contribute to the diversity of phytoplankton.

Presumably all these different shapes have some ecological meaning, said Andrew Barton, an assistant professor at Scripps Institution of Oceanography and the Biological Sciences Division at the University of California San Diego. Some shapes might be hard to eat, or maybe are advantageous for acquiring scarce resources.

Barton has just received the Simons Foundation Early Career Investigation in Marine Microbial Ecology and Evolution Award, which will support an interdisciplinary research project to attempt to answer this question.

The project will use a combination of underwater microscope data from the Scripps Pier Plankton Camera operated by the Jaffe Laboratory for Underwater Imaging, environmental data from the Southern California Coastal Ocean Observing System (SCCOOS), and numerical models that simulate plankton communities to understand the ecological reasons for the poorly understood diversity in phytoplankton shapes and sizes.

The Scripps Plankton Camera is an underwater microscope deployed at the Scripps Pier that uses real-time image processing and object detection to monitor plankton species and abundance. Barton and his team will combine data collected by the microscope and the SCCOOS environmental data to look for correlations between environmental conditions and abundance of different kinds of plankton over time. The information they gather will help researchers understand the local environment better. Barton and his team will also create numerical models to extrapolate the trends they see to the rest of the ocean.

We can take what we learn from the data at Scripps Pier and try to extrapolate that to a larger-scale perspective, Barton said. For example, where in the global ocean is it advantageous to be a spherical cell? Where it is advantageous to form large colonies of cells? We can try to make some estimates of how cell and colony morphology vary across the planet.

The outcomes of the project could also help answer oceanographic questions beyond phytoplankton ecology. Phytoplankton are an important part of the carbon cycle and their contributions to carbon dioxide uptake from the atmosphere and oxygen creation is a significant factor in most oceanographic and climate models.

Most models and theories about how phytoplankton do what they do are predicated on them being spheres, which is obviously untrue, Barton said.

The size and shape of organisms in the ocean is important in determining where carbon and energy go in the food web, and whether the carbon absorbed will be exported from the ocean's surface to the deep sea or sediments. Providing updated information on phytoplankton morphology and how it varies throughout the worlds oceans could improve sciences understanding of the carbon cycle.

For example, if you have a really dense large cell like a diatom, it will sink from the ocean's surface, resulting in a loss of organic matter, Barton said, whereas if you have a small cell, it may just stay near the surface and be recycled locally.

The interdisciplinary research will involve Jules Jaffe, a research oceanographer in the Marine Physical Laboratory at Scripps, Paul Roberts, an engineer in Jaffes lab, and Peter Franks, a professor of biological oceanography who will help the team estimate water column turbulence and understand how turbulence in the ocean shapes cell and colony morphology.

I'm really grateful for the Simons Foundation support and happy that we now have the team and the tools to do some compelling and important science, Barton said.

And as Barton is a relatively new faculty member, this big project will be an excellent opportunity for him to collaborate with other researchers at Scripps.

This is kind of a kick-off in terms of collaborating with a Scripps team and using data collected here at the institution, he said. Im very excited.

Mallory Pickett

The rest is here:
Around the Pier: The Bioengineering Behind the Beauty - Scripps Oceanography News

Clemson’s 15 patents in 2016 span bioengineering, advanced materials – Clemson Newsstand

CLEMSON, South Carolina Rapid diagnostic tests for point-of-care diagnostics, diabetic-resistant coatings, HIV inhibitors and an impact-resistant, corrosion-prohibiting coating were among the 15 innovations for which Clemson University researchers received patents in 2016.

Tanju Karanfil, vice president for research at Clemson University, says the patent awards are one example of the impact Clemson makes on the region. Image Credit: Craig Mahaffey / Clemson University

The Clemson University Research Foundation(CURF) facilitates and manages technology transfer for Clemson faculty. Collaboration between researchers and CURF has produced more than 150 patents that are nowavailable to the private sector for licensing.

The patent recipients received special recognition recently at an annual award event sponsored by theClemson Inventors Club, a select group of faculty chosen for their high level of research activity, which often produces inventions.

Invention and innovation in research are just a few ways Clemson impacts the world, said Tanju Karanfil, vice president for research at Clemson. Congratulations to all the inventors for their hard work and dedication to academic research.

Bob Quinn, executive director of theSouth Carolina Research Authority (SCRA) outlined the new vision for the organization.

The patent awards are a great representation of the innovation happening at Clemson, Quinn said. We were honored to be able to share how SCRA works with innovators to commercialize their technologies.

Our annual patent awards recognize the quality of the research being done at Clemson, said Casey Porto, executive director of the foundation. Its a privilege to honor these researchers and celebrate their contributions to innovation that starts at Clemson and moves into the marketplace.

For a complete list of 2016 Clemson patents and recipients,click here.

For a complete list of all patents awarded to Clemson faculty, click here.

END

Read this article:
Clemson's 15 patents in 2016 span bioengineering, advanced materials - Clemson Newsstand

Biochemistry Analyser Market to Reach a Valuation of US$ 4625.3 Mn in Revenues during 2016-2024 – MilTech

The clinical use of biochemistry analyzers in measurement solutions such as latex agglutination, ion-selective potentiometry, and colorimetric & photometric testing. In addition to this, accuracy of biochemistry analyzers in analyzing blood and urine samples has benefited pathology labs and diagnostic centers across the globe. Persistence Market Research predicts that the global demand for biochemistry analyzers will continue to soar on the grounds of such factors. A recent report published by Persistence Market Research projects that by the end of 2024, the global market for biochemistry analyzers will reach US$ 4,625.3 Mn in terms of value.

Key findings in the report cite that the use of chemistry analyzers spans from high-throughput clinical labs to point-of-care clinics, and its use for testing enzymes, electrolytes and proteins is gaining traction. The report current values the global biochemistry analyzer market at a little over US$ 3,000 Mn. During the forecast period, revenues generated through global sales of biochemistry analyzers are, thus, expected to soar at a steady CAGR of 5.5%.

Key Research Insights from the Report include:

Roche Diagnostics GmbH, Siemens AG, Beckman Coulter Inc., Abbott Diagnostics Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic, Inc., Randox Laboratories, Ltd., Awareness Technology, Inc., Transasia Biomedicals Ltd., and Nova Biomedical Corp. are profiled in the report as key players of global biochemistry analyzer market.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/6451

The report further reveals that fully-automated biochemistry analyzers will remain in great demand in the years to come. In 2017 and beyond, more than 85% of global biochemistry analyzer revenues will be accounted by sales of fully-automated biochemistry analyzers. Moreover, clinical diagnostics will also remain the largest application of biochemistry analyzers throughout the forecast period. Revenues accounted by global sales of biochemistry analyzers in clinical diagnostics are anticipated to register speedy growth at 5.7% CAGR. The report further identifies diagnostic centers as largest end-users of biochemistry analyzers in the world. On the other hand, rising number of point-of-care diagnostic labs instated in hospitals will render a key end-user of biochemistry analyzers. Together, hospitals and diagnostics centers will be responsible for procure over two-third of global biochemistry analyzers revenues through 2024.

Request to View Tables of Content @http://www.persistencemarketresearch.com/market-research/biochemistry-analyser-market/toc

The use of biochemistry analyzers in drug development applications is also expected to gain traction in the future. Based on modality, the report forecasts that in 2016, more than 70% of the market value was accounted by bench-top biochemistry analyzers. However, towards the end of the forecast period, the demand for bench-top modality will incur a marginal decline, while floor standing biochemistry analyzers will bring in over US$ 1,200 Mn revenues.

To Buy Full Report for a Single User @http://www.persistencemarketresearch.com/checkout/6451

More:
Biochemistry Analyser Market to Reach a Valuation of US$ 4625.3 Mn in Revenues during 2016-2024 - MilTech

‘Grey’s Anatomy’ Finale Has ‘Big News’ for Meredith & Riggs, and … – Moviefone

The "Grey's Anatomy" Season 13 finale should bring major updates on at least two relationship fronts, in addition to major events at the hospital itself.

"Grey's" hasn't given us much on Alex Karev (Justin Chambers) and Jo Wilson (Camilla Luddington) in a while, but that will soon change. The synopsis for the May 18 season finale mentions Alex making a "hard choice" in his relationship with Jo. In the same episode, we'll see Meredith Grey (Ellen Pompeo) share some "big news" with Nathan Riggs (Martin Henderson), bringing their relationship to "a turning point."

(!) She's not pregnant again, is she?

The finale is Episode 24 and, at this point, Episode 22 has yet to air. Here are the titles and synopses for the final three episodes of the season:

"Leave It Inside," Episode 22 (May 4) "April and Andrew consult with a fiery patient who has a giant, inoperable heart tumor. Meanwhile, Alex and Eliza are at odds over the treatment of a young patient, and Stephanie and Ben make decisions that could affect their careers."

"True Colors," Episode 23 (May 11) "The doctors of Grey Sloan encounter a difficult case involving a dangerous patient. Meanwhile, Owen receives life-changing news that pushes Amelia to step up to support him, and Alex attends a medical conference after making a shocking discovery."

"Ring of Fire," Episode 24 (May 18) "The doctors' lives are at risk after a dangerous patient escapes the hospital room. Alex must make a hard choice in his relationship with Jo while Meredith has some big news for Nathan that brings things to a turning point."

So Alex will make a "shocking discovery" in the episode before the finale's hard choice about Jo. Don't forget that Matthew Morrison was seen with Justin Chambers when they were filming Episode 23 -- both wearing suits -- and Morrison is still being eyed as Jo's abusive estranged husband. There's a good chance Morrison's character, Dr. Paul Stadler, plays into Alex's hard choice about Jo. And, yeah, he's probably at this same conference.

The Season 13 finale sounds pretty intense, beyond whatever happens on the relationship fronts. A dangerous patient on the loose is bad, and may be part of the "shocking" event Kelly McCreary (Maggie) talked about.

"Grey's Anatomy" airs Thursdays at 8 p.m. on ABC.

Want more stuff like this? Like us on Facebook.

Read more:
'Grey's Anatomy' Finale Has 'Big News' for Meredith & Riggs, and ... - Moviefone

‘Grey’s Anatomy’ Season 13, Episode 22 Spoilers: Leave It Inside … – EconoTimes

Greys Anatomy Season 13, Episode 22 Spoilers: Leave It Inside Alex Faces Another Possible Dismissal, Jail Time After Operating Without Consent

Greys Anatomy season 13s episode 22, titled Leave It Inside, will follow Alex as he faces another possible dismissal from the hospital as well as jail time after he operates on a young patient without parental consent.

The synopsis for Leave It Inside posted on TV Guide reads, April (Sarah Drew) and Andrew (Giacomo Gianniotti) consult with a fiery patient who has a giant, inoperable heart tumor. Meanwhile, Alex (Justin Chambers) and Eliza (guest star Marika Dominczyk) are at odds over the treatment of a young patient; and Stephanie (Jerrika Hinton) and Ben (Jason George) make decisions that could affect their careers.

The upcoming episode will be another challenging one for Dr. Alex Karev as he faces a possible dismissal from Grey Sloan Memorial Hospital over his latest decision. It was revealed in the promo that Alex will operate on a young boy despite his parents not giving parental consent.

Alex is set to clash with Eliza on the treatment of the young boy. It seems that Alex believes that only surgery can help the patient. Alex insisted that the boy took the train by himself to ask the doctors help.

The promo shows the parents being told that their son needs surgery. However, the mother replies, We dont believe in that sort of intervention. Of course, Alex and his colleagues are shocked at their decision.

In the end, Alex will risk his career by taking the case in his own hands despite the ethical consequences. The final scene in the promo shows the angry father screaming at Alex, You had no right to touch him!

Alex successfully dodged a previous assault case with Andrew that would have landed him in jail. He was also offered his old job back at Grey Sloan. However, it remains unclear whether he can avoid being charged a second time around.

Meanwhile, the upcoming episode will also feature big changes for Stephanie and Ben. According to Cartermatt, it seems that Stephanie will be ready to move on with her career and may leave Grey Sloan for better opportunities ahead.

Actress Jerrika Hinton, who took on the role of Dr. Stephanie Edwards since 2012, will not be returning as series regular for season 14. According to TVLine, Hinton has signed on to new television series and may return on Greys Anatomy but only on a guest-star basis.

Greys Anatomy season 13s episode 22, titled Leave It Inside, is scheduled to air on ABC on May 4, 2017. It was directed by Zetna Fuentes and written by Elisabeth R. Finch. It will be followed by episode 14, titled "True Colors, scheduled to be released on May 11 and directed by Kevin McKidd.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Read this article:
'Grey's Anatomy' Season 13, Episode 22 Spoilers: Leave It Inside ... - EconoTimes

CURE Pharmaceutical Adds Industry Veteran, Anti-Aging Specialist … – EconoTimes

CURE Pharmaceutical Adds Industry Veteran, Anti-Aging Specialist and Medicinal Cannabis Supporter, Alan Einstein, to Its Board of Directors

OXNARD, Calif., May 03, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (CURE), a leading disruptive drug delivery technology company researching cannabinoid molecules for various healthcare applications, today announces the appointment of Dr. Alan E. Einstein to its board of directors.

Dr. Alan Einstein, grandson to famed physicist Albert Einstein, has been practicing medicine since 1996. Currently working at EMC2Care in Alpharetta, Ga., he is considered a thought leader in metabolic syndrome and its role in weight gain and overall health and longevity. He has also conducted extensive research utilizing umbilical cord blood stem cells, with an interest in Parkinsons disease and assisted Senator David Shafer in writing and passing Georgias only Cord Blood stem cell bill. Furthermore, in July 2006, Dr. Einstein was appointed to the, Commission for Newborn Umbilical Cord Blood Research and Medical Treatment by Georgia Governor Sonny Perdue.

We here at CURE Pharmaceutical are always looking for innovators to be a part of our board of directors, to help us understand the needs in specific treatment areas, said Rob Davidson, CEO of CURE Pharmaceutical. Dr. Einsteins addition to our board allows for increased depth in our medical expertise as we continue to work to expand our technical capabilities across all these specific areas. We look forward to utilizing his specific knowledge and experience as we continue to rapidly grow.

Along with his work and knowledge in the areas of anti-aging and anti-inflammatory medicine, Dr. Einstein is a firm believer in the study of cannabis and cannabinoids for medicinal benefits. CURE is taking a leadership role in optimizing plant based cannabinoids with a strategy to bring new cannabinoid molecules to the market through the FDA regulatory approval process while utilizing the companys proprietary delivery technologies.

I am looking forward to being a part of CURE Pharmaceuticals board of directors. Their drug delivery technologies are innovative technologies that I believe will benefit a growing number of people who require alternate ways to take medications, instead of the standard pill, Dr. Einstein said. Additionally, I am excited to see the upcoming research and partnerships that the company is planning in the medicinal cannabinoid area, as this is a growing market area that needs more research to help prove the benefits of these molecules.

Dr. Einstein earned a bachelors of science degree in Physical Chemistry from The University of Florida. Subsequently, he earned his medical degree from The College of Osteopathic Medicine and Surgery in Des Moines, Iowa. Dr. Einstein then went on to complete his Internship and Residency training at The Johns Hopkins University School of Medicine/Sinai Hospital program in Internal Medicine, in Baltimore, MD.

About CURE Pharmaceutical Cure Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs). Cure has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm), the most advanced oral thin film on the market today. Cure has developed an array of products in cutting-edge delivery platforms. Cure is well positioned in thepharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Companys mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner.

For more information about CURE Pharmaceutical, please visit its website at http://www.curepharmaceutical.com.

Forward-looking statements This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements.Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

More here:
CURE Pharmaceutical Adds Industry Veteran, Anti-Aging Specialist ... - EconoTimes

Maritz Hires Chief Behavioral Officer – Daily Research News Online

In the US, research-led sales and marketing services company Maritz has appointed Charlotte Blank as Chief Behavioral Officer (CBO), tasked with leading its thought leadership, research, and the application of behavioral science.

The firm is based in St. Louis and its portfolio of services includes market and customer research; customer loyalty, sales incentives, employee rewards and recognition programs; and meeting, event and travel incentive services. Blank (pictured) previously led neuromarketing, social media and global branding initiatives during her ten years in the media and automotive industries, which included stints at Turner Broadcasting and General Motors. In her new role, she will also develop Maritz' network of academic partners and focus on opportunities for field research with these contacts and with clients.

CEO and Chairman Steve Maritz comments: 'At our core, we're a behavior company. The scientific study of human behavior is a central component of Maritz' DNA, and ingrained in the design of our client solutions. With Charlotte as our CBO, we can emphasize to the market and our clients the role behavioral science plays in powering our solutions and improving their business performance'.

Web site: http://www.maritz.com .

See more here:
Maritz Hires Chief Behavioral Officer - Daily Research News Online

This Founder is using Synbio to Revolutionize Genetic Medicine – Labiotech.eu (blog)

Oxford Genetics founder and CEO Ryan Cawood told me about his companys improvements to DNA design for better biologicals.

Last month at Synbiobeta, I caught up with Ryan Cawood, who created one of the most successful synthetic biology companies around, Oxford Genetics. Our direction actually took off from this conference, he told me. We saw that the cost of DNA synthesis is going to be driven down, so this was not a market for us to compete in.

Instead of focusing on making DNA engineering cheaper, Cawood decided to explore how to improve the quality of its products. Specific inspiration came in the form of frustration as he was trying to finish his PhD in genetics at Oxford University

I was making gene therapy plasmids, and they were increasingly hard to test because we just couldnt make them. They were 50 to 100 kilobases for different viruses with no standardization one section camefrom Spain, one section from the US, and one from the back of the freezerit was a sort of genetic car crash, as my PI, Len Seymour, called it.

As a company, we set out to improve this by focusing on DNA design we now help other companies working on therapeutics develop them better with SnapFast, a lego-like core DNA system.

In 2011, I formed the company by taking out bank loan. Then I negotiated a lab bench from local company in return for gene engineering for them. Finally, I built a website. Ive since obtained seven grants and connected with solid investors. Mercia Technologies has invested three times now the first time was in 2013 and on this next round, someone else will probably come in as well.

Len, my former lab PI, is still on the board as one of the cofounders. He was actually involved in founding two biotech companies before hand, one for oncolytic viruses (PsiOxus Therapeutics) and one for protein expression (The Native Antigen Company).

Cawoods lightning talk at Synbiobeta: fromsynthetic biology, Oxford Genetics is building up to improve biological drugsto reachpersonalised versions.

Well, our trajectory and plan was to build better DNA tech for the design and synthesis to discover and manufacture biologicals better. Fundamentally, youre always trying to build a tool to develop these better.

What Id like to see from the field is a major advancement of human therapeutics. There are four major challenges in biological development that were working to address: discovery, design, production and delivery basically every step.

We think Snapfast DNA will improve all of them because DNA is an integral part of each. So, we can absolutely use synbio to improve cell and gene therapies and biologics.

People who work in the area think of synbio as making things in algae, or making new genetic circuits etc, but dont necessarily see consequences for human health. The field has a huge role to play in tying the genetics of an individual human to a therapeutic treatment based on DNA. At the moment, there is no such pairing were a long way from that, but with synbio well get there.

We take a sort of blunt hammer approach now: its very inefficient therapeutically, and its a very inefficient use of government funds. By funding a better understanding of people, youll see significant gains intreatmentefficiencies.

The current approach is far too retrospective at the moment: we give a drug and then try to figure out why it worked in some people afterwards, or we just carry on giving it everyone knowing only a few people will benefit, in the future I hope we can predict efficacy and act upon that calculation.

Im still very much motivated by the therapeutic side of synthetic biology. Not everyone working at the company has a background in human genetics some come from working on archaea, but they all are oriented towards working towards therapeutics. Even my PA has first class degree in genetics.

DNA foundries are all the rage in synbio now, but we were much more interested in biology than physical manufacture that is, were much more focused on end goal versus how you get there. This thinking has changed the company a lot: instead of just making things, were designing things.

Images from Oxford Genetics,author at Synbiobeta, 04 April 2017, Mercia, & Sergei Drozd, Saibarakova Ilona /shutterstock.com

See the original post here:
This Founder is using Synbio to Revolutionize Genetic Medicine - Labiotech.eu (blog)

Smoking-related heart disease tied to effects of a single gene – Medical Xpress

May 1, 2017 Credit: Vera Kratochvil/public domain

Researchers have found a genetic explanation for how smoking can lead to coronary heart disease (CHD). Many people have a protective gene type that reduces levels of an enzyme connected to artery-clogging fatty plaques and CHD. However, in people carrying this gene, smoking counteracts the protective effect.

"Our finding suggest that interventions to inhibit this enzyme would be particularly beneficial for smokers, and they may also prove useful for anyone at heightened risk of coronary heart disease," said study leader Muredach P. Reilly, MBBCH, MSCE, the Herbert and Florence Irving Professor of Medicine (in Cardiology) and director of the Irving Institute for Clinical and Translational Research at Columbia University Medical Center (CUMC).

The study, the largest of its kind, was published online today in the journal Circulation.

Cigarette smoking is known to cause about one in five cases of CHD, and is linked to approximately 1.6 million deaths worldwide each year. But the precise mechanisms by which smoking leads to CHD has not been clear. To learn more about how genetics affect the interplay between smoking and heart disease, the researchers pooled genetic data on more than 140,000 people from 29 previous studies. They analyzed 45 small regions of the genome that have been previously associated with a heightened risk of CHD. They hypothesized that for some of these regions, the associated heart risk would be different in smokers than in non-smokers.

The analysis showed that a change in a single DNA "letter" on chromosome 15, near the gene that expresses an enzyme (ADAMTS7) produced in blood vessels, was associated with a 12 percent reduction in heart risk in non-smokers. However, smokers with this same variation had only a 5 percent lower risk of CHDreducing by over half the protective effect of this genetic variation.

DNA variations located near a gene sometimes inhibit the gene's activity, causing below-normal levels of the protein it produces. In this case, the researchers discovered that the single-letter DNA variation that protected patients from CHD resulted in a significant decline in the production of ADAMTS7.

In a separate recent mouse study, Dr. Reilly's lab demonstrated that genetic deletion of ADAMTS7 reduced the buildup of fatty plaques in arteries, suggesting that blocking the production or function of this enzyme might be a way to lower the risk of CHD.

In the current study, when the researchers applied a liquid extract of cigarette smoke to coronary artery cells, the cells' production of ADAMTS7 more than doubled, supporting the conclusion that smoking may counteract the genetic protection from CHD by increasing the level of ADAMTS7 in the artery wall.

"This has been one of the first big steps towards solving the complex puzzle of gene-environment interactions that lead to CHD," said lead author Danish Saleheen, PhD, assistant professor of biostatistics and epidemiology at the Perelman School of Medicine at the University of Pennsylvania.

In future studies, the researchers hope to establish exactly how the ADAMTS7 variants protect against CHD, how cigarette smoking affects the activity of the gene that produces the enzyme, and whether reducing or inhibiting ADAMTS7 can slow the progression of atherosclerosis due to cigarette smoking.

"This study is an important example of the emerging field of precision medicine and precision public health," said Dr. Reilly. "Through these large-scale genetic studies, we're beginning to understand the genetic variations that drive risk in response to certain environmental exposures or lifestyle behaviors. Not everyone reacts the same to the same exposures or behaviors. For example, some people who don't exercise develop diabetes while others do not. So, instead of saying there are rules for everybody, we can specify which interventions will be especially beneficial for specific populations or individuals and focus our health resources more efficiently."

The study is titled, "Loss of Cardio-Protective Effects at the ADAMTS7 Locus Due to Gene-Smoking Interactions."

Explore further: Scientists identify new therapeutic target for coronary heart disease

More information: Danish Saleheen et al. Loss of Cardio-Protective Effects at theLocus Due to Gene-Smoking Interactions, Circulation (2017). DOI: 10.1161/CIRCULATIONAHA.116.022069 , circ.ahajournals.org/content/early/2017/04/20/CIRCULATIONAHA.116.022069

Scientists investigating how certain genes affect an individual's risk of developing coronary heart disease have identified a new therapeutic target, according to research published today in The American Journal of Human ...

Natural genetic changes can put some people at high risk of certain conditions, such as breast cancer, Alzheimer's disease or high blood pressure. But in rare cases, genetic errors also can have the opposite effect, protecting ...

People who have heart disease risks in middle age - such as diabetes, high blood pressure or smoking - are at higher risk for dementia later in life, according to research presented at the American Stroke Association's International ...

Increased relative risks for coronary heart disease (CHD) have long been associated with smoking, and traditionally they have been dependent on the number of cigarettes smoked a day, smoking intensities, and total exposure ...

A novel gene therapy using CRISPR genome editing technology effectively targets cancer-causing "fusion genes" and improves survival in mouse models of aggressive liver and prostate cancers, University of Pittsburgh School ...

Researchers have found a genetic explanation for how smoking can lead to coronary heart disease (CHD). Many people have a protective gene type that reduces levels of an enzyme connected to artery-clogging fatty plaques and ...

The Tibetan people have inherited variants of five different genes that help them live at high altitudes, with one gene originating in the extinct human subspecies, the Denisovans. Hao Hu and Chad Huff of the University of ...

Physical activity can reduce the weight-gaining effects of the genetic variant that carries the greatest risk of obesity, report Mariaelisa Graff of the University of North Carolina at Chapel Hill, Tuomas Kilpelinen of ...

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a previously unrecognized step in stem cell-mediated muscle regeneration. The study, published in Genes and Development, provides new ...

An international study based at UT Southwestern Medical Center revealed a striking genetic-environmental interaction: Obesity significantly amplifies the effects of three gene variants that increase risk of nonalcoholic fatty ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:
Smoking-related heart disease tied to effects of a single gene - Medical Xpress

Novel gene editing approach to cancer treatment shows promise in mice – Medical Xpress

May 1, 2017 Killer T cells surround a cancer cell. Credit: NIH

A novel gene therapy using CRISPR genome editing technology effectively targets cancer-causing "fusion genes" and improves survival in mouse models of aggressive liver and prostate cancers, University of Pittsburgh School of Medicine researchers report in a study published online today in Nature Biotechnology.

"This is the first time that gene editing has been used to specifically target cancer fusion genes. It is really exciting because it lays the groundwork for what could become a totally new approach to treating cancer," explained lead study author Jian-Hua Luo, M.D., Ph.D., professor of pathology at Pitt's School of Medicine and director of its High Throughput Genome Center.

Fusion genes, which often are associated with cancer, form when two previously separate genes become joined together and produce an abnormal protein that can cause or promote cancer.

Luo and his team had previously identified a panel of fusion genes responsible for recurrent and aggressive prostate cancer. In a study published earlier this year in the journal Gastroenterology, the team reported that one of these fusion genes, known as MAN2A1-FER, also is found in several other types of cancer, including that of the liver, lungs and ovaries, and is responsible for rapid tumor growth and invasiveness.

In the current study, the researchers employed the CRISPR-Cas9 genome editing technology to target unique DNA sequences formed because of the gene fusion. The team used viruses to deliver the gene editing tools that cut out the mutated DNA of the fusion gene and replaced it with a gene that leads to death of the cancer cells. Because the fusion gene is present only in cancer cells, not healthy ones, the gene therapy is highly specific. Such an approach could come with significantly fewer side effects when translated to the clinic, which is a major concern with other cancer treatments such as chemotherapy.

To conduct the study, the researchers used mouse models that had received transplants of human prostate and liver cancer cells. Editing the cancer fusion gene resulted in up to 30 percent reduction in tumor size. None of the mice exhibited metastasis and all survived during the eight-week observation period. In contrast, in control mice treated with viruses designed to cut out another fusion gene not present in their tumors, the tumors increased nearly 40-fold in size, metastasis was observed in most animals, and all died before the end of the study.

The new findings suggest a completely new way to combat cancer. "Other types of cancer treatments target the foot soldiers of the army. Our approach is to target the command center, so there is no chance for the enemy's soldiers to regroup in the battlefield for a comeback," said Luo.

Another advantage over traditional cancer treatment is that the new approach is very adaptive. A common problem that renders standard chemotherapies ineffective is that the cancer cells evolve to generate new mutations. Using genome editing, the new mutations could be targeted to continue fighting the disease, Luo noted.

In the future, the researchers plan to test whether this strategy could completely eradicate the disease rather than induce the partial remission observed in the current study.

Explore further: A new approach to target an 'undruggable' prostate cancer driver

More information: Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene, Nature Biotechnology (2017). nature.com/articles/doi:10.1038/nbt.3843

New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers.

Using the gene-editing system known as CRISPR, MIT researchers have shown in mice that they can generate colon tumors that very closely resemble human tumors. This advance should help scientists learn more about how the disease ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...

Angiosarcoma is a malignant cancer of the endothelial cells of blood or lymphatic vessels. Cutaneous angiosarcoma, a form of skin cancer, commonly occurs on the scalp of elderly people and can rapidly metastasize to the liver, ...

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.

A novel gene therapy using CRISPR genome editing technology effectively targets cancer-causing "fusion genes" and improves survival in mouse models of aggressive liver and prostate cancers, University of Pittsburgh School ...

Researchers have found a genetic explanation for how smoking can lead to coronary heart disease (CHD). Many people have a protective gene type that reduces levels of an enzyme connected to artery-clogging fatty plaques and ...

The Tibetan people have inherited variants of five different genes that help them live at high altitudes, with one gene originating in the extinct human subspecies, the Denisovans. Hao Hu and Chad Huff of the University of ...

Physical activity can reduce the weight-gaining effects of the genetic variant that carries the greatest risk of obesity, report Mariaelisa Graff of the University of North Carolina at Chapel Hill, Tuomas Kilpelinen of ...

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a previously unrecognized step in stem cell-mediated muscle regeneration. The study, published in Genes and Development, provides new ...

An international study based at UT Southwestern Medical Center revealed a striking genetic-environmental interaction: Obesity significantly amplifies the effects of three gene variants that increase risk of nonalcoholic fatty ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original post:
Novel gene editing approach to cancer treatment shows promise in mice - Medical Xpress

First US success of nonhuman primate gene editing – Medical Xpress

May 1, 2017 Credit: CC0 Public Domain

Mice have been and will continue to be good base models for human medicinal advances. However, their size and some of their physiological differences leave them lacking in important areas of human medicine, including neurological and reproductive research.

In a study led by Michigan State University, scientists have shown that gene editing using CRISPR/Cas9 technology can be quite effective in rhesus monkey embryos - the first time this has been demonstrated in the U.S.

The results, published in the current issue of Human Molecular Genetics, open the door for pursuing gene editing in nonhuman primates as models for new therapies, including pharmacological, gene- and stem cell-based therapies, said Keith Latham, MSU animal science professor and lead author of the study.

"Our paper is the first in the U.S. to publish on the use of this technology in nonhuman primate embryos," he said. "Using nonhuman primate embryos is important because the closer we can approximate the human condition in the animal model, the better the chances of developing successful treatments as well as limiting risks that may be encountered in clinical trials."

While mice are mammals, they bear litters rather than individual offspring. Their anatomy and physiology differ in many respects from humans. While many advances in understanding diseases have been made first using mouse models, making the leap from a successful mouse study to clinical trials can be difficult or impossible for some areas of research.

"If scientists want to test drugs for dementia, Alzheimer's or autism, ideal models would react similarly to humans in regards to the reduction of symptoms, outbreak of side effects, such as enduring the same lesions as humans do, or exhibiting similar behavioral characteristics," said Latham, who's with the College of Agriculture and Natural Resources and an MSU AgBioResearch scientist.

"Nonhuman primates are much better models for such diseases. And in terms of some surgical procedures, implants, developing prosthetics, or other therapies, nonhuman primates can prove better suited than rodents."

CRISPR has opened the door to do gene editing in many species other than mice. Developing this technology in nonhuman primates in the U.S. would allow more scientists in this country to incorporate these models into their research, he added.

The advances will allow scientists to move forward and tackle some of the technical barriers related to the research. Other issues that may be later resolved are the commitment to increased costs and longer waiting times when using nonhuman primates.

Fruit flies, often used in genetic studies, reproduce in two weeks. Rodents, with pre-disposed genetic characteristics, can be easily ordered and shipped to laboratories within days. Committing to raising nonhuman primates can cost around $15,000 and can take as long as 4-6 years to have a mature monkey with the desired genetic characteristics.

The high-efficiency of gene editing that scientists are now able to achieve makes it worth the cost and the wait, Latham said.

To conduct the research, Latham partnered with the California National Primate Research Center, where the monkey embryos were produced, in collaboration with his co-investigator Dr. Catherine VandeVoort, an expert in nonhuman primate reproduction. Dr. Daniel Bauer, at Harvard Medical School, Boston Children's Hospital and Dana-Farber Cancer Institute also collaborated on the study.

The resources offered by the CNPRC were crucial for this work, Latham said.

"Extreme amounts of care go into maintaining the well-being of the monkeys," he said. "They follow strict protocols to ensure this is a priority. So being able to conduct the science here at Michigan State while partnering with the center is the best combination of science and animal welfare."

Explore further: First non-human primate model for severe combined immunodeficiency

While many insights are gained into diseases and genetic disorders from rodent models, there is a pressing need to find models that can more accurately represent disease progression in the human body, such as non-human primates. ...

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

A major review of nonhuman primate use in medical research has been conducted in the UK by Professor Sir Patrick Bateson, who is the president of the Zoological Society of London and an ethnologist from Cambridge University, ...

Research in nonhuman primates (NHP) has led to some of the most significant medical advancements known today and will be essential to continued biomedical progress, according to the new white paper "The Critical Role of Nonhuman ...

Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying ...

A novel gene therapy using CRISPR genome editing technology effectively targets cancer-causing "fusion genes" and improves survival in mouse models of aggressive liver and prostate cancers, University of Pittsburgh School ...

Researchers have found a genetic explanation for how smoking can lead to coronary heart disease (CHD). Many people have a protective gene type that reduces levels of an enzyme connected to artery-clogging fatty plaques and ...

The Tibetan people have inherited variants of five different genes that help them live at high altitudes, with one gene originating in the extinct human subspecies, the Denisovans. Hao Hu and Chad Huff of the University of ...

Physical activity can reduce the weight-gaining effects of the genetic variant that carries the greatest risk of obesity, report Mariaelisa Graff of the University of North Carolina at Chapel Hill, Tuomas Kilpelinen of ...

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a previously unrecognized step in stem cell-mediated muscle regeneration. The study, published in Genes and Development, provides new ...

An international study based at UT Southwestern Medical Center revealed a striking genetic-environmental interaction: Obesity significantly amplifies the effects of three gene variants that increase risk of nonalcoholic fatty ...

Adjust slider to filter visible comments by rank

Display comments: newest first

I saw a monkey video with 4' long tail. Similarly, there are monkeys with almost NO TAIL. So, They must Start with Changing Tail sizes of Rhesus Monkeys resembling those of different species! That will NOT hurt The Monkey & Will Tell us WHY we Don't have Tails! Laymen Too will Then Believe/Trust Gene Editing!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
First US success of nonhuman primate gene editing - Medical Xpress

Gene sequencing at Yale finding personalized root of disease; new center opens in West Haven – New Haven Register

WEST HAVEN >> Our genes define our individuality, including what diseases to which we may be susceptible.

In just a few days, gene-sequencing machines can map all of a persons genes, revealing the cause of a genetic illness and even suggesting the best possible treatment.

On Monday, the Yale School of Medicine, partnering with Yale New Haven Hospital, took the next step toward personalized medicine, cutting the ribbon on its Center for Genome Analysis on Yales West Campus.

Dr. Murat Gunel, professor of genetics and neuroscience in the medical school, gave a vivid example of how gene sequencing can save lives:

Advertisement

About three months ago a baby was born in New Haven with a really, really significant skin disease that we had to transfer him to the intensive care unit. And he was dying, and we didnt know what was wrong with him, Gunel said. In six days we were able to sequence his genome, understand his disease and he is at home playing with his mother now.

The baby suffered from dystrophic epidermolysis bullosa, which makes the skin extremely fragile, and its caused by a mutation in just one gene: COL7A1. Gunel said Dr. Keith Choate first saw the baby on a Saturday and by Friday had the diagnosis. This is a daily occurrence, Gunel said.

Choate said the genetic analysis showed the infant had a mild case of the disease, which was limited to the hands and feet. He is receiving advanced wound care, Choate said.

The pair of NovaSeq 6000 gene-sequencing machines that are churning out this information with three more on the way will help researchers find treatments and cures for cancers, prenatal diseases and others at a faster and faster pace.

Of 20,000 genes in the human genome, 57 have been identified for which preventive measures can be taken or treatment can be prescribed if an abnormality or mutation is found. For example, mutations in the BRCA1 or BRCA2 genes increase a womans risk of developing breast or uterine cancer.

We are sequencing every cancer at Smilow now, understanding what is specific for that cancer and giving treatment specific to that individual, Gunel said. We want to take from these specific diseases not only for prenatal, not only for newborn, not only for cancer, but [to] understand the health of an individual. We want to make Connecticut the healthiest state in the nation by sequencing and understanding the differences between all of us.

Dr. Robert Alpern, dean of the Yale School of Medicine, said, The idea is that you can know the total sequence of a patient and then follow their history, their health, what happens to them and then correlate them together so that someday we will be able to predict everything about ones health just from their DNA sequence.

Yale has done so much for New Haven, so much for New Haven County and now so much for this country, said Senate Republican President Pro Tem Len Fasano of North Haven.

Referring to the ability to map a persons genome within days, Fasano said, You can take that and figure out how the environment affects different lives by looking at different gene structure, comparing to different parts of the country or whether its an urban area versus a suburban area. The research that can stem from this is pretty amazing when you think of it.

The growing field also is a boon to the states economy. Senate Democratic President Pro Tem Martin Looney of New Haven said, This commitment to the advancement of health and medicine will have far-reaching and positive impacts on our economy and overall well-being for years to come. We know were going to need data scientists, health information specialists, clinical analysts, genomic counselors, to name just a few of the specialties that are going to create huge opportunities for new employment in our state.

Marna Borgstrom, CEO of Yale New Haven Health, which includes the hospital, said, Theres great work being done here and our interest has been, who does this apply to and how can we make this available to patients? And with our partners at the medical school were committed to providing unparalleled value to people we serve, and part of value is giving people outcomes that are meaningful to them.

And so you start to think about areas like prenatal diagnoses, like certain newborn diseases, difficult cancers and the ability to take all of the drugs and the treatments and the information thats out there but actually create a specialized plan for each patient as each patients going to respond differently, she said.

Call Ed Stannard at 203-680-9382.

Continue reading here:
Gene sequencing at Yale finding personalized root of disease; new center opens in West Haven - New Haven Register

Chemistry controlled on tiniest scale can create hollow nanoparticles – Science News

Blame oxidation for rusted bridges and browned avocados. But this fundamental process can be harnessed for good, too and now scientists have scored front-row seats that could show them how.

Researchers watched at near-atomic resolution as iron nanoparticles transformed into iron oxide not rust in this case, but related compounds. That closeup view could help scientists better control oxidation and design corrosion-resistant materials or new kinds of catalysts, the researchers report in the April 21 Science.

This is the first time the oxidation process has been observed in such detail, says Andreu Cabot, a physicist at the Catalonia Institute for Energy Research in Barcelona who wasnt part of the study.

When a metal oxidizes, its atoms mix and mingle with oxygen atoms to create a new material. That process is perhaps most famous for creating rust, which flakes and corrodes. But iron can oxidize in a variety of ways, some of which are useful.

For instance, chemist Yugang Sun and his colleagues at Temple University in Philadelphia are trying to create hollow iron oxide nanoparticles that could serve as catalysts to speed up chemical reactions or as vessels to deliver drugs or store energy in chemical form. But making these nanoshells from iron nanoparticles requires precise control over the oxidation process.

If oxygen atoms work their way into an iron nanoparticle faster than the iron atoms can diffuse out, that nanoparticle becomes a tight, solid ball, Sun says. If the iron diffuses out faster than the oxygen comes in, on the other hand, it becomes the hollow sphere that Suns lab wants.

Controlling that process is difficult because it has been unclear exactly how these shells form on an atomic level, Sun says. Scientists havent been able to watch it happen, because high-powered microscopy techniques can disrupt the reaction or show the action in only two dimensions.

Suns team tried a different approach to observe the reaction, by shooting X-rays at many identical iron nanoparticles suspended in a liquid. Each time the X-rays hit a different material moving from the liquid to the solid, for instance they scattered.

Story continues after graphic

Researchers measured the way X-rays bounced off oxidizing nanoparticles and then used computer models to reconstruct where atoms were moving over the course of the chemical reaction. As the nanoparticles oxidized, small holes developed and merged together to eventually form a hollow iron oxide shell

By tracking how the X-rays bounced off many small, uniform iron nanoparticles, the researchers were able to reconstruct where individual atoms were going as the particles oxidized into hollow shells over the course of several hours.

The researchers watched as the iron moved out of the center of the nanoparticle to react with the oxygen, initially forming many small holes inside the nanoparticle. Eventually, those empty spaces merged together to form one big void in the middle of the nanoparticle.

The impact of this paper is more than just the hollow [nanoparticles], says Yadong Yin, a chemist at the University of California, Riverside who wasnt involved in the research. The imaging technique itself will be a useful way to study how other types of nanoparticles form something scientists still dont understand well, he says. It can be used to gain insight into other types of oxidation, too.

Read the original here:
Chemistry controlled on tiniest scale can create hollow nanoparticles - Science News